Hemogenyx Pharmaceuticals PLC Further re. Grant of Options (7514Z)

TIDMHEMO

RNS Number : 7514Z

Hemogenyx Pharmaceuticals PLC

22 September 2020

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Further re. Grant of Options

On 21 August 2020, the Company announced that the Directors had granted the Company's co-founder and CEO Dr Vladislav Sandler options over a total of 5,000,000 ordinary shares of 1p each in the capital of the Company ("Share Options"). The Directors have now resolved to adjust the exercise price of the Share Options to 9p to reflect the Company's share price at the time of the grant. All other details regarding the grant of the Share Options remain the same.

Enquiries:

 
 Hemogenyx Pharmaceuticals plc           https://hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive 
  Officer & Co-Founder                   headquarters@hemogenyx.com 
 Peter Redmond, Director                 peter.redmond@hemogenyx.com 
 
                                         Tel: +44 (0)20 3470 
 SP Angel Corporate Finance LLP           0470 
 Matthew Johnson, Vadim Alexandre, 
  Soltan Tagiev 
 
                                         Tel: +44 (0)20 7469 
 Peterhouse Capital Limited               0930 
 Lucy Williams, Duncan Vasey, Charles 
  Goodfellow

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):

 
 1.   Details of PDMR/person closely associated with them 
 a)   Name                        Dr Vladislav Sandler 
     --------------------------  --------------------------------------- 
 b)   Position/status             CEO, Executive Director 
     --------------------------  --------------------------------------- 
 c)   Initial notification/       Amendment to prior notification no. 
       amendment                   00117904 
     --------------------------  --------------------------------------- 
 2.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of              Options over ordinary shares of 1p 
       the financial               of Hemogenyx Pharmaceuticals plc 
       instrument                  Identification code GB00BYX3WZ24 
     --------------------------  --------------------------------------- 
 b)   Nature of the               Grant of options 
       transaction 
     --------------------------  --------------------------------------- 
 c)   Price(s) and                 Price(s)    Volume(s) 
       volume(s)                    GBP0.09     5,000,000 
                                               ---------- 
     --------------------------  --------------------------------------- 
 d)   Aggregated information       Price(s)          Volume(s) 
       - Aggregated                 N/A - variable    5,000,000 
       volume                                        ---------- 
       - Price 
     --------------------------  --------------------------------------- 
 e)   Date of the transaction     20/08/2020 
     --------------------------  --------------------------------------- 
 f)   Place of the                Outside of a trading venue 
       transaction 
     --------------------------  ---------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHPPUBCBUPUGGP

(END) Dow Jones Newswires

September 22, 2020 07:52 ET (11:52 GMT)

Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024